SVB Wealth LLC Sells 113,330 Shares of AbbVie Inc. $ABBV

SVB Wealth LLC trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 52.5% during the 2nd quarter, Holdings Channel reports. The firm owned 102,349 shares of the company’s stock after selling 113,330 shares during the period. AbbVie comprises 1.0% of SVB Wealth LLC’s investment portfolio, making the stock its 21st biggest position. SVB Wealth LLC’s holdings in AbbVie were worth $18,998,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Marshall & Sullivan Inc. WA purchased a new stake in shares of AbbVie during the second quarter worth about $25,000. TD Capital Management LLC boosted its stake in AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares during the period. Spurstone Advisory Services LLC purchased a new stake in AbbVie during the 2nd quarter valued at approximately $28,000. Financial Gravity Companies Inc. purchased a new stake in AbbVie during the 2nd quarter valued at approximately $36,000. Finally, Bear Mountain Capital Inc. raised its position in shares of AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after buying an additional 173 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ABBV shares. Piper Sandler reiterated an “overweight” rating and issued a $289.00 price target (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. BMO Capital Markets boosted their target price on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research report on Friday, September 12th. Berenberg Bank upgraded AbbVie from a “hold” rating to a “buy” rating and raised their price target for the company from $170.00 to $270.00 in a report on Wednesday, September 17th. HSBC set a $225.00 price objective on AbbVie in a report on Thursday, October 2nd. Finally, UBS Group boosted their price target on shares of AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $241.85.

AbbVie Trading Down 1.1%

Shares of ABBV opened at $226.24 on Monday. The company’s fifty day simple moving average is $228.30 and its 200-day simple moving average is $208.54. The company has a market cap of $399.85 billion, a P/E ratio of 171.39, a P/E/G ratio of 1.22 and a beta of 0.36. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is presently 496.97%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.